EFFECT OF A TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT ON LIVER BIOCHEMICAL PROFILES

被引:16
作者
CRIPPIN, JS [1 ]
SCHMIDT, RD [1 ]
NIBLETT, RL [1 ]
REES, CR [1 ]
机构
[1] BAYLOR UNIV,MED CTR,DEPT RADIOL,DALLAS,TX 75246
关键词
BRAIN; DISEASES; LIVER; FUNCTION; SHUNTS; PORTOSYSTEMIC;
D O I
10.1016/S1051-0443(95)72842-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: Transjugular intrahepatic portosystemic shunts (TIPS) have markedly simplified the care of patients with refractory variceal bleeding. Follow-up of liver biochemical profiles, however, has not been done in a prospective fashion. PATIENTS AND METHODS: Twenty-nine patients undergoing TIPS placement for refractory variceal bleeding underwent serial laboratory test's and assessment of encephalopathy to determine the effect of TIPS. Prothrombin time and aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, serum albumin, serum creatinine, and venous ammonia levels were checked prior to the procedure, at the time of discharge, and at 3 weeks, 3 months, and 6 months following the procedure. RESULTS: There was no statistically significant change in any of the obtained laboratory values at up to 6 months of follow-up. The change in aspartate aminotransferase level approached but did not reach statistical significance at the time of discharge and was thought to be secondary to hepatocellular trauma associated with the procedure. New onset of encephalopathy occurred in 18.2% of patients and was easily controlled with medical therapy. CONCLUSIONS: TIPS does not appear to have a significant effect on the liver biochemical profile with short-term follow-up. Hepatic encephalopathy does occur, however, in a significant number of patients but is easily controlled with medical therapy.
引用
收藏
页码:461 / 464
页数:4
相关论文
共 13 条
[1]  
Zemel, Katzen, Becker, Et al., Percutaneous transjugular portosystemic shunt, JAMA, 266, pp. 390-393, (1991)
[2]  
Ring, Lake, Roberts, Et al., Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation, Ann Intern Med, 116, pp. 304-309, (1992)
[3]  
LaBerge, Ring, Gordon, Et al., Creation of transjugular intrahepatic portosystemic shunts with the Wallstent endoprosthesis: results in 100 patients, Radiology, 187, pp. 413-420, (1993)
[4]  
Conn, Leevy, Vlahcevic, Et al., A comparison of lactulose and neomycin in the treatment of portal-systemic encephalopathy: a double-blind controlled trial, Gastroenterology, 72, pp. 573-583, (1977)
[5]  
Redeker, Geller, Reynolds, Hepatic wedge pressure blood flow vascular resistance and oxygen consumption in cirrhosis before and after end-to-side portacaval shunt, Journal of Clinical Investigation, 37, pp. 606-618, (1958)
[6]  
Starzl, Porter, Kashiwagi, Et al., Portal hepatatrophic factors, diabetes mellitus, and acute liver atrophy, hypertrophy, and regeneration, Surg Gynecol Obstet, 141, pp. 843-858, (1975)
[7]  
Starzl, Porter, Watanabe, Et al., The effects of insulin, glucagon, and insulin/glucagon infusion upon liver morphology and cell division after complete portacaval shunt in dogs, Lancet, 1, pp. 821-825, (1976)
[8]  
Mutchnick, Lerner, Conn, Portal-systemic encephalopathy and portacaval anastomosis: a prospective controlled investigation, Gastroenterology, 66, pp. 1005-1019, (1974)
[9]  
Resnick, Iber, Tishihara, Et al., A controlled study of the therapeutic portacaval shunt, Gastroenterology, 67, pp. 843-857, (1974)
[10]  
Reynolds, Donovan, Mickelsen, Et al., Results of a twelveyear randomized trial of portacaval shunt in patients with alcoholic liver disease and bleeding varices, Gastroenterology, 80, pp. 1005-1011, (1981)